
A study on medicine shortages in the Netherlands found that disease and costs were the two most affected elements, with 30% and 20% of shortages rated high on these elements, respectively. The study used a framework of economic, clinical, and patient outcomes to assess the impact of medicine shortages on patients. Direct impact, represented by alternative product and disease, was rated high for 30% of the shortages, while indirect impact, represented by costs, susceptibility, and number of patients, was rated high for 17% of the shortages. No significant differences in impact scores were found based on product characteristics.
Recent Posts
NICE Endorses Obecabtagene Autoleucel Therapy for Adult Relapsed B-Cell Leukaemia
NICE Backs Obecabtagene Autoleucel
The National Institute for Health and Care Excellence (NICE) recommended obecabtagene autoleucel therapy, a UK-developed chimeric antigen receptor (CAR) T-cell trea...
Accelerating Access to Latin America Innovative Therapies Through Collaboration and Innovation
Accelerating Access to Latin America Innovative Therapies
In this update we outline a strategic vision for transforming Latin America's healthcare systems through innovation, collaboration, and equitable access, with a stron...
Rethinking HEOR Market Access Integration: A Call for Early Engagement Before Phase 3
Early HEOR Market Access Integration
In this brief interview on ISPOR, Indranil Bagchi asserts that HEOR market access integration must occur earlier in drug development—ideally before Ph...